3PBIOVIAN And INC Partner To Expand Access To Oncology Treatments In Colombia Through Biosimilar Development

Pamplona - 3PBIOVIAN, a leading Contract Development and Manufacturing Organization (CDMO), and the National Cancer Institute (Instituto Nacional de Cancerología) in Colombia (INC) has signed a contract to carry out the development of a biosimilar monoclonal antibody (mAb) for an oncology indication, marking the first biosimilar mAb to be developed specifically for expanding access to oncology treatments in Colombia.

The agreement covers the full process development, including cell line development, process and analytical method development, process scale-up, and technology transfer to the client’s facilities in Colombia, where manufacturing will ultimately take place to supply product for patient care.

For 3PBIOVIAN, the contract represents a significant milestone in strengthening its track record in full mammalian development, from cell line creation through industrial-scale process transfer. It also allows 3PBIOVIAN to participate in this highly important initiative to expand patient access to valuable therapeutics against cancer. For its Colombian partner, the project is a strategic step forward for the country’s biopharmaceutical industry, aligned with national efforts to build local biomanufacturing capacity and reduce dependence on imported biologics.

“We are proud to contribute to this project, which truly reflects 3PBIOVIAN’s purpose: to enable global access to high-quality biopharmaceuticals,” said Dámaso Molero, Group CEO. “This collaboration reinforces our experience in mammalian development programs and our commitment to international partnerships that make a real impact on patients’ lives.”

The project represents an innovative initiative for Colombia, driven by the ambition to expand access to affordable biologic medicines. The production of this biosimilar mAb is expected to improve access to oncology treatments for Colombian patients and to strengthen the country’s biotechnological sovereignty.

With this agreement, 3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.

About 3PBIOVIAN

The National 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Their service offerings include protein expression and production platforms based on microbial strains and mammalian cells, plasmid DNA, viral vectors for adenovirus and adenoassociated virus for gene therapy, and cell therapy products. Additionally, they provide fill and finish services for recombinant proteins and viral vectors. The company has manufacturing facilities in Pamplona-Noáin, Spain, and Turku, Finland, efficiently supporting the diverse needs of their clients, covering everything from preclinical and clinical supply to large-scale commercial manufacturing for drug substance and drug product. www.3pbiovian.com

About INC

The National Cancer Institute (Instituto Nacional de Cancerología) in Colombia is a state entity at the national level, which works for the comprehensive control of cancer through patient care, research, human talent training, and the development of public health actions. An institution whose vision is to be a benchmark in 2025 for its achievements in reducing the incidence and mortality of cancer, based on innovation and technology, with ethical and sustainable actions and with a motivated and committed human talent. From its creation in 1934 to the present day, when its 85th anniversary is celebrated, the institute has been considered an advisory body to the Ministry of Health and Social Protection, a high-complexity hospital, a teaching center and a research center, becoming a reference organization for Colombia and Latin America on the subject of Cancer. www.cancer.gov.co